Trial Profile
A Randomized, Double Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naive Metastatic Castration Resistant Prostate Cancer Patients Treated With Docetaxel Plus Prednisolone Who Have Progressed on Enzalutamide Alone
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Docetaxel; Prednisolone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PRESIDE
- Sponsors Astellas Pharma Europe Ltd
- 04 Apr 2024 Status changed from active, no longer recruiting to completed.
- 08 Mar 2024 This study has been completed in Czechia, according to European Clinical Trials Database record.
- 31 Jan 2024 Planned End Date changed from 31 Jan 2024 to 29 Feb 2024.